![Bupropion Orion modified release tablet ENG SmPC](http://s1.studyres.com/store/data/005366448_1-562c8f0f49d42e8c52473cc99da8b36d-300x300.png)
Bupropion Orion modified release tablet ENG SmPC
... of treatment. Patients with depression should be treated for a sufficient period of at least 6 months to ensure that they are free from symptoms. Insomnia is a very common adverse event which is often transient. Insomnia may be reduced by avoiding dosing at bedtime (provided that there is at least 2 ...
... of treatment. Patients with depression should be treated for a sufficient period of at least 6 months to ensure that they are free from symptoms. Insomnia is a very common adverse event which is often transient. Insomnia may be reduced by avoiding dosing at bedtime (provided that there is at least 2 ...
product monograph including patient
... It is not known whether NITRO-DUR can cause fetal harm when administered to pregnant women or can affect reproductive capacity. Therefore, use NITRO-DUR only if the potential benefit justifies the risk to the fetus. NITRO-DUR (Nitroglycerin Transdermal System) ...
... It is not known whether NITRO-DUR can cause fetal harm when administered to pregnant women or can affect reproductive capacity. Therefore, use NITRO-DUR only if the potential benefit justifies the risk to the fetus. NITRO-DUR (Nitroglycerin Transdermal System) ...
Handbook of Anti-Tuberculosis Agents
... humans, and absorption, distribution, metabolism and excretion (ADME). However, this database is designed to be an overview of TB drug information rather than an in-depth comprehensive review of all aspects of TB treatment. For further information on any specific compound or any specific aspect of the ...
... humans, and absorption, distribution, metabolism and excretion (ADME). However, this database is designed to be an overview of TB drug information rather than an in-depth comprehensive review of all aspects of TB treatment. For further information on any specific compound or any specific aspect of the ...
Critical Reviews in Oral Biology & Medicine
... et aL, 1989). However, when tested in five patients with oral lichen planus, only slight clinical improvement was noted. An aqueous suspension of triamcinolone acetonide 0.1% was used recently as an oral rinse in the treatment of 46 patients with symptomatic oral lichen planus (Vincent et al, 1990). ...
... et aL, 1989). However, when tested in five patients with oral lichen planus, only slight clinical improvement was noted. An aqueous suspension of triamcinolone acetonide 0.1% was used recently as an oral rinse in the treatment of 46 patients with symptomatic oral lichen planus (Vincent et al, 1990). ...
Multiple dose pharmacokinetics of caffeine administered in chewing
... study is essentially maintained across repeated doses. Also, the pharmacokinetic parameters seem to be dose independent. These findings suggest that both the physical and mental performance deficits that result from sleep loss or fatigue could be reversed quickly by caffeine administered in a gum fo ...
... study is essentially maintained across repeated doses. Also, the pharmacokinetic parameters seem to be dose independent. These findings suggest that both the physical and mental performance deficits that result from sleep loss or fatigue could be reversed quickly by caffeine administered in a gum fo ...
Comparing Inhaled Corticosteroids
... budesonide, flunisolide, fluticasone propionate, and triamcinolone acetonide. Extensive information has been compiled on the differences in pharmacologic profiles among these products. Both in vivo and in vitro testing suggests that these 5 inhaled corticosteroids may have clinically relevant differ ...
... budesonide, flunisolide, fluticasone propionate, and triamcinolone acetonide. Extensive information has been compiled on the differences in pharmacologic profiles among these products. Both in vivo and in vitro testing suggests that these 5 inhaled corticosteroids may have clinically relevant differ ...
Michael Nailor - Hartford Hospital
... not enough: mitigating the risk of frequent intra-hospital transports from the ICU. New England Surgical Society September 2012. Accepted for Platform Presentation. Raman K*, Nailor MD, Nicolau DP, Aslanzdeh J, Kuti JL. Antibiotic discontinuation is not associated with mortality in suspected ventila ...
... not enough: mitigating the risk of frequent intra-hospital transports from the ICU. New England Surgical Society September 2012. Accepted for Platform Presentation. Raman K*, Nailor MD, Nicolau DP, Aslanzdeh J, Kuti JL. Antibiotic discontinuation is not associated with mortality in suspected ventila ...
LOSARTAN POTASSIUM AMLODIPINE CAMSYLATE
... the administration of losartan potassium 50 mg titrated to 100 mg significantly reduced proteinuria by 42%. Fractional excretion of albumin and IgG also was significantly reduced. In these patients, losartan maintained glomerular filtration rate and reduced filtration fraction. In postmenopausal hyp ...
... the administration of losartan potassium 50 mg titrated to 100 mg significantly reduced proteinuria by 42%. Fractional excretion of albumin and IgG also was significantly reduced. In these patients, losartan maintained glomerular filtration rate and reduced filtration fraction. In postmenopausal hyp ...
warning: addiction, abuse, and misuse
... Monitor closely, especially upon initiation or following a dose increase. Instruct patients to swallow KADIAN capsules whole to avoid exposure to a potentially fatal dose of morphine. (5.2) Accidental ingestion of KADIAN, especially by children, can result in fatal overdose of morphine. (5.2) Pr ...
... Monitor closely, especially upon initiation or following a dose increase. Instruct patients to swallow KADIAN capsules whole to avoid exposure to a potentially fatal dose of morphine. (5.2) Accidental ingestion of KADIAN, especially by children, can result in fatal overdose of morphine. (5.2) Pr ...
Taclonex - LEO Pharma
... Betamethasone dipropionate was evaluated for effects when orally administered to pregnant rats from gestation day 6 through day 20 postpartum at dosages of 0, 100, 300, and 1000 mcg/kg/day. Mean maternal body weight was significantly reduced on gestation day 20 in animals dosed at 300 and 1000 mcg/k ...
... Betamethasone dipropionate was evaluated for effects when orally administered to pregnant rats from gestation day 6 through day 20 postpartum at dosages of 0, 100, 300, and 1000 mcg/kg/day. Mean maternal body weight was significantly reduced on gestation day 20 in animals dosed at 300 and 1000 mcg/k ...
TUSSIONEX Pennkinetic (hydrocodone polistirex
... to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the d ...
... to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the d ...
Prescribing Information
... Possible clinically significant adverse reactions from greater exposure of concomitant drugs or components of ZEPATIER. Significant decrease of elbasvir and grazoprevir plasma concentrations which may lead to reduced therapeutic effect of ZEPATIER and possible development of resistance. See Tabl ...
... Possible clinically significant adverse reactions from greater exposure of concomitant drugs or components of ZEPATIER. Significant decrease of elbasvir and grazoprevir plasma concentrations which may lead to reduced therapeutic effect of ZEPATIER and possible development of resistance. See Tabl ...
MAXIDOL® Liquid Gels
... Adults (12-65 years): 1 caplet/capsule every 8 - 12 hours. For individuals over 65 years, 1 capsule every 12 hours. Do not take more than 2 capsules in a 24 hour period. Drink a full glass of water with each dose. Under 12 years: Children under 12 should not take this drug. The safety in pediatric u ...
... Adults (12-65 years): 1 caplet/capsule every 8 - 12 hours. For individuals over 65 years, 1 capsule every 12 hours. Do not take more than 2 capsules in a 24 hour period. Drink a full glass of water with each dose. Under 12 years: Children under 12 should not take this drug. The safety in pediatric u ...
Intranasal (IN) Medication Administration MBED Clinical Practice
... parameters of dexmedetomidine, nor is there a difference in the pharmacokinetic parameters between young (18 to 40 years), middleaged (41 to 65 years), and elderly (>65 years) subjects. Severe renal dysfunction has no effect on the elimination of dexmedetomidine, but its impact on the metabolites ha ...
... parameters of dexmedetomidine, nor is there a difference in the pharmacokinetic parameters between young (18 to 40 years), middleaged (41 to 65 years), and elderly (>65 years) subjects. Severe renal dysfunction has no effect on the elimination of dexmedetomidine, but its impact on the metabolites ha ...
Pharmacokinetics, toxicity, and cytochrome P450
... and P. berghei-infected mice [8]. The labeled complex distributed to all organs of both healthy and infected mice but with high intensity in liver, followed by lung, stomach, large intestine, and kidney. Accumulation in spleen was markedly noticeable in the infected mice. Plumbagin-labeled complex w ...
... and P. berghei-infected mice [8]. The labeled complex distributed to all organs of both healthy and infected mice but with high intensity in liver, followed by lung, stomach, large intestine, and kidney. Accumulation in spleen was markedly noticeable in the infected mice. Plumbagin-labeled complex w ...
Fentanyl Data Sheet Oct 13
... narcotics, alcohol and general anaesthetics, will have additive or potentiating effects with fentanyl. When patients have received such medicines, the dose of fentanyl required will be less than usual. Likewise, following the administration of fentanyl the dose of other CNS depressant medicines shou ...
... narcotics, alcohol and general anaesthetics, will have additive or potentiating effects with fentanyl. When patients have received such medicines, the dose of fentanyl required will be less than usual. Likewise, following the administration of fentanyl the dose of other CNS depressant medicines shou ...
OMNARIS Full Prescribing Information
... Teratogenic Effects: Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. OMNARIS Nasal Spray should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Experience with oral corticosteroids since their introduction i ...
... Teratogenic Effects: Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. OMNARIS Nasal Spray should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Experience with oral corticosteroids since their introduction i ...
... and a sinusoidal wave form with an inspiration to expiration ratio (I:E) of 1:2. The spacers had been treated before use by washing in a mild detergent, air-drying and subsequent priming with 15 puffs of spray at least 24 h before the test. Four pMDI and four spacers were tested using a Latin-square ...
Vol 1 Pg 2 EXECUTIVE SUMMARY
... FDA states in it’s proposed rule, “at their (ie, OTC acetaminophen-containing products) recommended doses, these products are only rarely associated with serious adverse events relative to the number of consumers who use these products.” [71 FR 77314 at 77315]. Elsewhere in FDA’s proposed rule, FDA ...
... FDA states in it’s proposed rule, “at their (ie, OTC acetaminophen-containing products) recommended doses, these products are only rarely associated with serious adverse events relative to the number of consumers who use these products.” [71 FR 77314 at 77315]. Elsewhere in FDA’s proposed rule, FDA ...
Reynolds-Psych-Panels-11-20-12
... Patients who are homozygous for the CYP1A2*1F/*1F genotype may exhibit even higher rates of CYP1A2 enzymatic activity and have been described as ultra-rapid metabolizers for olanzapine. As an example, carriers of CY1A2*1F with the hyperinduction phenotype may exhibit as much as 50% lower than expect ...
... Patients who are homozygous for the CYP1A2*1F/*1F genotype may exhibit even higher rates of CYP1A2 enzymatic activity and have been described as ultra-rapid metabolizers for olanzapine. As an example, carriers of CY1A2*1F with the hyperinduction phenotype may exhibit as much as 50% lower than expect ...
Levitra
... for successful intercourse, and hardness were significantly improved compared to placebo for the tested doses of 10 mg and 20 mg at all time points. Improved erectile function response rates as based on GAQ were 57% on 10 mg, and 60% on 20 mg compared to 9% on placebo at 3 months. In the subgroup of ...
... for successful intercourse, and hardness were significantly improved compared to placebo for the tested doses of 10 mg and 20 mg at all time points. Improved erectile function response rates as based on GAQ were 57% on 10 mg, and 60% on 20 mg compared to 9% on placebo at 3 months. In the subgroup of ...
see Warnings and - Boehringer Ingelheim
... Clinically significant hyponatremia (sodium <125 mmol/L) can develop during oxcarbazepine use. In the 14 controlled epilepsy studies 2.5% of oxcarbazepine-treated patients (38/1,524) had a sodium of less than 125 mmol/L at some point during treatment, compared to no such patients assigned placebo or ...
... Clinically significant hyponatremia (sodium <125 mmol/L) can develop during oxcarbazepine use. In the 14 controlled epilepsy studies 2.5% of oxcarbazepine-treated patients (38/1,524) had a sodium of less than 125 mmol/L at some point during treatment, compared to no such patients assigned placebo or ...
Diagnosis and anti-infective therapy of periodontitis
... affected by a kind of periodontitis with prevalence rates and severity greater among men than women and among blacks than whites. Among those affected, between 3 and 15% are susceptible to a rapid and advanced loss of periodontal attachment. They may develop aggressive forms of periodontitis, which ...
... affected by a kind of periodontitis with prevalence rates and severity greater among men than women and among blacks than whites. Among those affected, between 3 and 15% are susceptible to a rapid and advanced loss of periodontal attachment. They may develop aggressive forms of periodontitis, which ...
panadol osteo data sheet
... volunteers with respect to dose-corrected AUC(0-t) and AUC(0-inf) in both the fed and fasted states following administration of a single dose. This indicates that the extent of paracetamol absorption from PANADOL OSTEO was equivalent to that of standard immediate release paracetamol. Food had little ...
... volunteers with respect to dose-corrected AUC(0-t) and AUC(0-inf) in both the fed and fasted states following administration of a single dose. This indicates that the extent of paracetamol absorption from PANADOL OSTEO was equivalent to that of standard immediate release paracetamol. Food had little ...
Role of topical, subconjunctival, intracameral, and irrigative
... for ophthalmic use is besifloxacin, with the objective of eliminating the contribution to resistance development due to systemic use [29–31]. Another purported advantage of this formulation is the use of DuraSite, a mucoadhesive polymer designed to prolong the adherence of the drug to the ocular sur ...
... for ophthalmic use is besifloxacin, with the objective of eliminating the contribution to resistance development due to systemic use [29–31]. Another purported advantage of this formulation is the use of DuraSite, a mucoadhesive polymer designed to prolong the adherence of the drug to the ocular sur ...
Ofloxacin
Ofloxacin is a synthetic antibiotic of the fluoroquinolone drug class considered to be a second-generation fluoroquinolone.Ofloxacin was first patented in 1982 (European Patent Daiichi) and received approval from the U.S. Food and Drug Administration (FDA) on December 28, 1990. Ofloxacin is sold under a wide variety of brand names as well as generic drug equivalents, for oral and intravenous administration. Ofloxacin is also available for topical use, as eye drops and ear drops (marketed as Ocuflox and Floxin Otic respectively in the United States and marketed as Optiflox, eylox respectively in Jordan and Saudi Arabia).Ofloxacin is a racemic mixture, which consists of 50% levofloxacin (the biologically active component) and 50% of its “mirror image” or enantiomer dextrofloxacin.Ofloxacin has been associated with adverse drug reactions, such as tendon damage (including spontaneous tendon ruptures) and peripheral neuropathy (which may be irreversible); tendon damage may manifest long after therapy had been completed, and, in severe cases, may result in lifelong disabilities.